NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
Aardvark Therapeutics, Inc. anticipates completing its clinical trial for ARD-101, a treatment aimed at addressing hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS), on April 1, 2026. The trial, listed as NCT06828861 and currently in Phase 3, aims to assess the efficacy and safety of ARD-101 compared to a placebo. Approximately 90 participants will receive the treatment or placebo over a span of 12 weeks while documenting their experiences. This trial is expected to provide critical insights into the management of hyperphagia, a significant concern for individuals with PWS.
Clinical Trial Completion